SAN DIEGO, September 13, 2016 -- Neuropore Therapies, Inc. (NPT) announced today that they have successfully achieved a key program milestone in their collaboration with UCB.  After successful completion of a randomized, double-blind, placebo controlled single ascending dose clinical study and additional non-clinical studies, UCB has awarded NPT^TM a progression milestone of $5 million. 

 "We are very pleased with UCB’s decision to proceed with the development of this novel therapeutic candidate that initially arose from Neuropore’s drug-discovery platform.  This is an important milestone for Neuropore and reflects UCB’s continued commitment to a promising therapeutic opportunity for the treatment of Parkinson’s disease,” commented Doug Bonhaus, Ph.D., Neuropore’s COO.

For full press release: http://www.businesswire.com/news/home/20160913005482/en/Neuropore-Therapies-NPT-Announces-Achievement-Key-Program